Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)

人类乳酸脱氢酶 A (LDHA) 抑制剂作为抗癌药物的先进开发（化学生物学联盟/NCI 实验治疗合作组织）

• 批准号: 10255282
• 负责人: Matthew Hall
• 金额: $ 30.57万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10255282
• 关键词: Advanced Development; Antineoplastic Agents; Biology; Biotechnology; Cell division; Chemicals; Collaborations; Drug Targeting; Enzymes; Exhibits; Human; Investigational Therapies; Licensing; Mediation; Metabolic; Pathway interactions; Preparation; Publications; Reaction; Research; Technology; Work; anti-cancer; cancer cell; cancer type; cell growth; in vitro activity; in vivo; inhibitor/antagonist; lactate dehydrogenase A; model development; novel; tumor

This collaborative team - composed of groups from NCI, CBC/NExT, U Penn, Vanderbilt, UAB, UNM and NCATS - aims to build on previous research by uncovering novel inhibitors of LDHA for anticancer indications. During this period, the NCATS group, as part of the LDHA collaborative team, has worked to characterize the mechanism of action of the novel LDH inhibitors, guide in vivo efficacy model development, assess in vitro activity of novel LDH degraders, and assess in vitro activity of novel tumor concentrating LDH inhibitors. Multiple publications are under preparation and technology is under negotiation for out-licensing with a small biotech.

这个合作小组-由NCI，CBC/NExT，U Penn，范德比尔特，UAB，UNM和NCATS的小组组成-旨在通过发现LDHA的抗癌适应症的新型抑制剂来建立以前的研究。在此期间，NCATS小组作为LDHA协作团队的一部分，致力于表征新型LDH抑制剂的作用机制，指导体内疗效模型开发，评估新型LDH降解剂的体外活性，并评估新型肿瘤浓缩LDH抑制剂的体外活性。目前正在编写多份出版物，并正在与一家小型生物技术公司谈判技术转让许可。